Speaker Profile

Biography
Vivek Subbiah, MD, joined Sarah Cannon Research Institute (SCRI) in 2023, and serves as chief, Early-Phase Drug Development. In his role, Dr. Subbiah oversees SCRI's nine drug development units and leads the expansion of early-phase capabilities and programs across SCRI's growing research network. Dr. Vivek Subbiah comes to SCRI from the University of Texas MD Anderson Cancer Center where he was an associate professor in the Department of Investigational Cancer Therapeutics. During his near 15-year tenure there, Dr. Vivek Subbiah held several leadership roles including Executive Director, Medical Oncology Research, MD Anderson Cancer Network as well as Clinical Medical Director, Division of Cancer Medicine where he oversaw both the outpatient and inpatient clinical care delivery operations for the Phase I program. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase III trials and co-investigator in over 200 clinical trials.